163 related articles for article (PubMed ID: 20583968)
21. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
22. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.
Owens TS; Dodds H; Fricke K; Hanna SK; Crews KR
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):65-74. PubMed ID: 12668072
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
24. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
25. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L
Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516
[TBL] [Abstract][Full Text] [Related]
27. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
[TBL] [Abstract][Full Text] [Related]
28. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
[TBL] [Abstract][Full Text] [Related]
29. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.
Tallman MN; Ritter JK; Smith PC
Drug Metab Dispos; 2005 Jul; 33(7):977-83. PubMed ID: 15833930
[TBL] [Abstract][Full Text] [Related]
30. MDR1 transporter protects against paraquat-induced toxicity in human and mouse proximal tubule cells.
Wen X; Gibson CJ; Yang I; Buckley B; Goedken MJ; Richardson JR; Aleksunes LM
Toxicol Sci; 2014 Oct; 141(2):475-83. PubMed ID: 25015657
[TBL] [Abstract][Full Text] [Related]
31. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
32. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
33. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
Warner DL; Burke TG
J Chromatogr B Biomed Sci Appl; 1997 Mar; 691(1):161-71. PubMed ID: 9140770
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
[TBL] [Abstract][Full Text] [Related]
35. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Chen C; Lin J; Smolarek T; Tremaine L
Drug Metab Dispos; 2007 Oct; 35(10):1725-9. PubMed ID: 17640956
[TBL] [Abstract][Full Text] [Related]
38. [In vitro and in vivo stability of 9-nitrocamptothecin lactone form in rats].
Chen J; Ping QN; Guo JX; Liu L; Chu XZ; Song MM
Yao Xue Xue Bao; 2005 Oct; 40(10):888-92. PubMed ID: 16408803
[TBL] [Abstract][Full Text] [Related]
39. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
40. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
